

# Zensar Technologies

**HOLD**

Driving innovation and growth through AI-powered transformation

## Summary

Zensar Technologies delivered steady Q2FY26 results, with revenue at USD 162.8mn, up 4.2% YoY, and maintaining mid-tear EBITDA margins despite annual wage hikes and one-time bonuses through operational efficiency gains and favorable forex. The Banking, Financial Services, and Healthcare segments showed growth, while the TMT vertical declined sharply due to reallocation of spending by technology customers. AI momentum accelerated, with 28% of order bookings backed by AI, and the ZenseAI platform gaining traction, particularly in legacy modernization & analytics. Management remains positive on pipeline conversion outside TMT and continues investing in AI skills and domain-specific solutions. Voluntary attrition stayed below 10% for the third consecutive quarter, and the company's focus on offshore delivery and utilization supported margins amidst macroeconomic uncertainties. Overall, Zensar is executing a client-centric, AI-led growth strategy while tactically managing sectoral headwinds. We retain a positive long-term view but maintain a **HOLD**, with a target price of Rs 894 (25.1x FY27E EPS).

## Key Highlights and Investment Rationale

- Demand of AI:** strategy centers on scaling AI talent, launching the ZenseAI platform, and embedding AI into core client solutions to drive productivity and innovation. The ZenseAI platform offers agentic AI capabilities, industry-specific agents for legacy modernization, fraud detection, automation, and real-time analytics.
- Margins/dealwins:** Margins improved with gross margin at 31.0% and EBITDA at 15.4%, despite wage hikes; deal pipeline remains strong with selective large deals and AI-led order growth.

TP	Rs894			Key Stock Data	
CMP	Rs798				
Potential upside/downside	12%				
Previous Rating	HOLD				
Price Performance (%)					
	-1m	-3m	-12m		
Absolute	3.8	0.8	14.4		
Rel to Sensex	0.1	(3.4)	9.2		
V/s Consensus				Shareholding Pattern (%)	
EPS (Rs)	FY26E	FY27E		Promoters	49.0
IDBI Capital	31	36		FII	13.3
Consensus	31	35		DII	21.1
% difference	(1.4)	2.7		Public	16.6

Year	FY23	FY24	FY25	FY26E	FY27E	(Rs mn)
Revenue	48,483	49,019	52,075	57,175	63,397	
Change (yoY, %)	14	1	6.2	9.8	10.9	
EBITDA	5,523	8,718	8,286	8,576	9,858	
Change (yoY, %)	(16)	58	(5)	4	15	
EBITDA Margin(%)	11.4	17.8	15.9	15.0	15.6	
Adj.PAT	3,275	6,651	6,368	7,055	8,054	
EPS (Rs)	14	29	28.2	31	36	
Change (yoY, %)	(21)	103	(4)	11	14	
PE(x)	62	30	31.8	29	25	
Dividend Yield (%)	1	1	1	1	1	
EV/EBITDA (x)	35	22	24	22	19	
RoE (%)	12	21	17	15	16	
RoCE (%)	12	21	18	16	16	

Source: IDBI Capital Research;

**Saptarshi Mukherjee**

saptarshi.mukherjee@idbicapital.com  
+91-22-4069 1853

### Concall Highlights

- Revenue for the quarter stood at USD 162.8mn, +0.5%/+4.2% USD terms; Healthcare uptick of 3.9% QoQ & BFSI +5.6% QoQ, while, TMT declined by 9.9% QoQ. Manufacturing and consumer services at +0.1% QoQ. Geographically, Growth across US, UK/Europe, South Africa; weakness concentrated in TMT-heavy US accounts.
- EBITDA 15.4%, +20 bps QoQ despite salary hikes & one-time bonus; driven by higher utilization, better offshore mix, and cost control. Gross margin improved to 31%, +50 bps QoQ.
- The Service lines: Cloud Infra & Security +14.1% YoY, Data Engineering & Analytics +9.2% YoY, Products & Platforms +4.3% YoY, Enterprise Apps -2.6% YoY.
- Utilization improved to 84.8%, +200 bps YoY, +50 bps QoQ. Attrition stable at ~9.8% (third consecutive quarter <10%). Order Book at USD 158.7mn; Book-to-Bill 1.02 for H1; Q2 softness attributed to seasonal renewals and deal-timing delays.
- Management flags no structural weakness outside TMT; pipeline described as “one of the highest qualified in company’s history” with large deals in advanced stages.
- TMT commentary: Clients shifting OpEx to data center / GPU CapEx, leading to vendor rationalization & productivity-led headcount cuts; management sees this as structural, not temporary.
- AI traction strong: 28% of Q2 bookings were AI-influenced (vs 21% in Q1). Launch of ZenseAI (agentic AI platform) showing use-case traction in modernization, fraud analytics, testing automation, computer vision defect detection & API factory operations. 5,000+ employees trained in GenAI / agentic AI; leadership AI capability program ongoing.
- Cash & investments at US 293mn post-dividend; DSO at 75 days (up due to FX).
- H1 non-delivery headcount increased by ~40 roles, spread across sales & support; management does not see cost concern.
- Outlook: Q3 to see seasonal furloughs, though lower impact due to reduced TMT exposure. Mid-teens EBITDA margin commitment reiterated. No specific revenue guidance, but management remains “positive excluding TMT headwind”.

## Exhibit 1: Financial snapshot

(Rs mn)

Year-end: March	Q2FY26	Q1FY26	QoQ (%)	Q2FY25	YoY (%)
<b>Revenues (US\$ mn)</b>	<b>162.8</b>	<b>162.0</b>	<b>0.5</b>	<b>156.2</b>	<b>4.2</b>
<b>Revenues</b>	<b>14,213</b>	<b>13,850</b>	<b>2.6</b>	<b>13,080</b>	<b>8.7</b>
COGS	9,801	9,627	1.8	9,406	4.2
Gross profit	4,412	4,223	4.5	3,674	20.1
SG&A	2,212	2,117	4.5	1,663	33.0
<b>EBITDA</b>	<b>2,200</b>	<b>2,106</b>	<b>4.5</b>	<b>2,011</b>	<b>9.4</b>
Depreciation & amortization	252	231	9.1	297	(15.2)
EBIT	1,948	1,875	3.9	1,714	13.7
Other income	454	531	(14.5)	366	24.0
PBT	2,402	2,406	(0.2)	2,080	15.5
Tax	580	586	(1.0)	522	11.1
Minority interest	0	0	n.m.	0	n.m.
<b>Adjusted net profit</b>	<b>1,822</b>	<b>1,820</b>	<b>0.1</b>	<b>1,558</b>	<b>16.9</b>
Exceptional item	0	0	n.m.	0	n.m.
<b>Reported net profit</b>	<b>1,822</b>	<b>1,820</b>	<b>0.1</b>	<b>1,558</b>	<b>16.9</b>
<b>Recurring EPS (Rs)</b>	<b>8.02</b>	<b>8.01</b>	<b>0.1</b>	<b>6.86</b>	<b>16.8</b>
<hr/>					
<b>As % of net revenue</b>					
Gross profit	31.0	30.5			28.1
SG&A	15.6	15.3			12.7
EBITDA	15.5	15.2			15.4
EBIT	13.7	13.5			13.1
Reported net profit	12.8	13.1			11.9
Tax rate	24.1	24.4			25.1

Source: Company; IDBI Capital Research

### Exhibit 2: Earnings revision table



Year to March	FY26E			FY27E		
	New	Old	Ch (%)	New	Old	Ch (%)
Revenue (US\$mn)	657	670	-1.9%	725	742	-2.4%
Revenue (Rsmn)	57,175	58,264	-1.9%	63,397	64,964	-2.4%
EBIT (Rsmn)	7,490	8,280	-9.5%	8,654	9,428	-8.2%
EBIT margin (%)	13.1%	14.2%	-111 bps	13.7%	14.5%	-86 bps
EPS (Rs)	31.2	32.0	-2.5%	35.6	36.0	-1.1%

Source: Company; IDBI Capital Research

### Exhibit 3: Large clients trend

Year-end: March	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26
US\$1 mn+	84	85	86	86	87	84	82	84
US\$5 mn+	32	31	31	32	34	33	32	32
US\$10 mn+	14	14	14	15	14	14	16	15
US\$20 mn+	4	4	4	4	5	6	6	6


Source: Company; IDBI Capital Research

**Exhibit 4: Q2FY26 Revenue growth to be flat at 0.5%**

*Source: Company; IDBI Capital Research*
**Exhibit 5: Q2Y26 EBIT margin up by 17 bps QoQ basis**

*Source: Company; IDBI Capital Research*

**Exhibit 6: Revenue growth across various segments (%)**


Parameters	% of revenue	QoQ growth (in USD)	YoY growth (in USD)
		0.5%	4.2%
Geography		QoQ growth (in USD)	YoY growth (in USD)
US	66.6%	-2.0%	2.68%
Europe	21.5%	5.4%	6.20%
Africa	11.9%	6.8%	9.76%
Service-Line		QoQ growth	QoQ growth
AMS	77.8%	-0.9%	1.7%
IMS	22.2%	5.7%	14.0%
Verticals		QoQ growth	QoQ growth
Hi Tech	20.0%	-9.9%	-6.9%
Manufacturing & Consumer services	25.2%	0.1%	0.2%
BFSI	43.6%	5.6%	11.1%
Healthcare	11.2%	3.3%	11.2%

Source: Company; IDBI Capital Research

**Exhibit 7: Utilization remained flattish at 84.8%**


Source: Company; IDBI Capital Research

## Exhibit 8: One-year forward PER trend



Source: Company; IDBI Capital Research

## Financial Summary

### Profit & Loss Account

(Rs mn)

Year-end: March	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Net sales</b>	<b>42,437</b>	<b>48,483</b>	<b>49,019</b>	<b>52,075</b>	<b>57,175</b>	<b>63,397</b>
<i>Change (yoY, %)</i>	12.2	14	1	6	10	11
Operating expenses	(35,872)	(42,960)	(40,301)	(43,789)	(48,599)	(53,539)
<b>EBITDA</b>	<b>6,565</b>	<b>5,523</b>	<b>8,718</b>	<b>8,286</b>	<b>8,576</b>	<b>9,858</b>
<i>Change (yoY, %)</i>	-4.1	(16)	58	(5)	4	15
<i>Margin (%)</i>	15.5	11.4	17.8	15.9	15.0	15.6
Depreciation	(1,848)	(1,830)	(1,338)	(989)	(1,086)	(1,205)
<b>EBIT</b>	<b>4,717</b>	<b>3,693</b>	<b>7,380</b>	<b>7,297</b>	<b>7,490</b>	<b>8,654</b>
Interest paid	(353)	(280)	(209)	(167)	(157)	(148)
Other income	1,377	1,028	1,588	1,250	1,950	2,050
<b>Pre-tax profit</b>	<b>5,741</b>	<b>4,441</b>	<b>8,759</b>	<b>8,380</b>	<b>9,283</b>	<b>10,556</b>
Tax	(1,525)	(1,166)	(2,108)	(2,011)	(2,228)	(2,502)
<i>Effective tax rate (%)</i>	26.6	26.3	24.1	24.0	24.0	23.7
Minority Interest	(54.0)	-	-	-	-	-
<b>Net profit</b>	<b>4,162</b>	<b>3,275</b>	<b>6,651</b>	<b>6,368</b>	<b>7,055</b>	<b>8,054</b>
Exceptional items	-	-	-	-	-	-
<b>Adjusted net profit</b>	<b>4,162</b>	<b>3,275</b>	<b>6,651</b>	<b>6,368</b>	<b>7,055</b>	<b>8,054</b>
<i>Change (yoY, %)</i>	19.2	(21)	103	(4)	11	14
EPS	18.3	14.5	29.4	28.2	31.2	35.6
Dividend per sh	5.0	5.0	5.5	9.0	9.4	10.7
<i>Dividend Payout %</i>	27.3	34.6	18.7	32	30	30

Balance Sheet							(Rs mn)
Year-end: March	FY22	FY23	FY24	FY25	FY26E	FY27E	
<b>Shareholders' funds</b>	<b>26,592</b>	<b>28,984</b>	<b>34,523</b>	<b>40,697</b>	<b>45,635</b>	<b>51,273</b>	
Share capital	452	453	453	454	454	454	
Reserves & surplus	26,140	28,531	34,070	40,243	45,181	50,819	
<b>Total Debt</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	
Other liabilities	3,544	2,866	2,319	2,210	2,210	2,210	
<b>Curr Liab &amp; prov</b>	<b>8,299</b>	<b>8,582</b>	<b>8,540</b>	<b>8,822</b>	<b>8,333</b>	<b>8,965</b>	
Current liabilities	6,693	6,248	6,331	5,963	5,756	6,108	
Provisions	1,606	2,334	2,209	2,859	2,577	2,857	
<b>Total liabilities</b>	<b>11,843</b>	<b>11,448</b>	<b>10,859</b>	<b>11,032</b>	<b>10,543</b>	<b>11,175</b>	
<b>Total equity &amp; liabilities</b>	<b>38,712</b>	<b>41,210</b>	<b>46,481</b>	<b>51,729</b>	<b>56,178</b>	<b>62,448</b>	
Net fixed assets	12,858	11,735	10,393	11,709	12,095	12,468	
Investments	-	-	-	-	-	-	
Other non-curr assets	3,226	6,291	10,144	6,874	7,127	7,316	
<b>Current assets</b>	<b>22,628</b>	<b>23,184</b>	<b>25,944</b>	<b>33,146</b>	<b>36,957</b>	<b>42,664</b>	
Inventories	-	-	-	-	-	-	
Sundry Debtors	7,967	7,298	7,320	7,901	8,538	9,467	
Cash and Bank	8,559	7,280	7,241	7,436	10,232	14,789	
Loans and advances	1,636	4,509	6,509	12,537	12,537	12,537	
<b>Total assets</b>	<b>38,712</b>	<b>41,210</b>	<b>46,481</b>	<b>51,729</b>	<b>56,178</b>	<b>62,448</b>	

Cash Flow Statement							(Rs mn)
Year-end: March	FY22	FY23	FY24	FY25	FY26E	FY27E	
Pre-tax profit	5,741	4,441	8,759	8,380	9,283	10,556	
Depreciation	1,803	1,838	1,559	1,146	1,043	1,151	
Tax paid	(1,572)	(1,585)	(2,249)	(1,991)	(2,431)	(2,641)	
Chg in working capital	832	(1,921)	(2,064)	(6,327)	(1,126)	(297)	
Other operating activities	(1,031)	-	(4,726)	39	(233)	(264)	
<b>Cash flow from operations (a)</b>	<b>5,772</b>	<b>2,773</b>	<b>1,279</b>	<b>1,247</b>	<b>6,536</b>	<b>8,505</b>	
Capital expenditure	(3,330)	(715)	(217)	(2,462)	(1,428)	(1,525)	
Chg in investments	-	-	-	-	-	-	
Other investing activities	1,121	(1,920)	-	-	-	-	
<b>Cash flow from investing (b)</b>	<b>(2,209)</b>	<b>(2,635)</b>	<b>(217)</b>	<b>(2,462)</b>	<b>(1,428)</b>	<b>(1,525)</b>	
Equity raised/(repaid)	1	1	-	1	-	-	
Debt raised/(repaid)	-	-	-	-	-	-	
Dividend (incl. tax)	(1,135)	(1,132)	(1,246)	(2,041)	(2,116)	(2,416)	
Chg in minorities	(64)	501	321	(1,099)	-	-	
Other financing activities	(792)	(787)	(176)	(258)	-	-	
<b>Cash flow from financing (c)</b>	<b>(1,991)</b>	<b>(1,417)</b>	<b>(1,101)</b>	<b>(3,397)</b>	<b>(2,116)</b>	<b>(2,416)</b>	
<b>Net chg in cash (a+b+c)</b>	<b>1,573</b>	<b>(1,279)</b>	<b>(39)</b>	<b>(4,613)</b>	<b>2,991</b>	<b>4,564</b>	

### Financial Ratios

Year-end: March	FY22	FY23	FY24	FY25	FY26E	FY27E
Book Value (Rs)	117.1	128.0	152.6	179.9	201.8	226.7
<i>Adj EPS (Rs)</i>	18.3	14.5	29.4	28.2	31.2	35.6
<i>Adj EPS growth (%)</i>	19.5	-21.1	103.4	-4.2	10.8	14.2
<i>EBITDA margin (%)</i>	15.5	11.4	17.8	15.9	15.0	15.6
<i>Pre-tax margin (%)</i>	13.5	9.2	17.9	16.1	16.2	16.7
<i>Net Debt/Equity (x)</i>	-0.3	-0.3	-0.2	-0.2	-0.2	-0.3
<i>ROCE (%)</i>	16.4	11.7	20.9	18.1	15.7	16.2
<i>ROE (%)</i>	16.6	11.8	20.9	16.9	15.5	15.7
<b>DuPont Analysis</b>						
Asset turnover (x)	1.2	1.2	1.1	1.1	1.0	1.0
Leverage factor (x)	1.5	1.4	1.4	1.3	1.2	1.2
<i>Net margin (%)</i>	9.8	6.8	13.6	12.2	12.3	12.7
<b>Working Capital &amp; Liquidity ratio</b>						
Inventory days	0	0	0	0	0	0
Receivable days	69	55	55	55	55	55
Payable days	32	24	28	29	24	24

### Valuations

Year-end: March	FY22	FY23	FY24	FY25	FY26E	FY27E
PER (x)	48.8	61.8	30.4	31.8	28.7	25.1
Price/Book value (x)	7.6	7.0	5.9	5.0	4.4	3.9
EV/Net sales (x)	4.6	4.0	4.0	3.7	3.4	3.0
EV/EBITDA (x)	29.6	35.3	22.4	23.5	22.4	19.0
<i>Dividend Yield (%)</i>	0.6	0.6	0.6	1.0	1.0	1.2

Source: Company; IDBI Capital Research

Dealing

(91-22) 6836 1111

dealing@idbic平al.com

**Key to Ratings Stocks:****BUY:** 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.**IDBI Capital Markets & Securities Ltd.****Equity Research Desk**

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 4069 1700; Fax: (91-22) 2215 1787; Email: info@idbic平al.com

**SEBI Registration:** BSE & NSE (Cash & FO) – INZ000007237, NSDL – IN-DP-NSDL-12-96, Research – INH000002459, CIN – U65990MH1993GOI075578**Compliance Officer:** Pushkar Vartak; Email: compliance@idbic平al.com; Telephone: (91-22) 4069 1907**Disclaimer**

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.

**Most Important Terms and Conditions**

To refer the Most Important Terms and Conditions (MITC) click on the link; [https://idbidirect.in/Common\\_Controls/SEBI\\_MITC\\_RA.pdf](https://idbidirect.in/Common_Controls/SEBI_MITC_RA.pdf)

### Analyst Disclosures

I, Saptarshi Mukherjee, hereby certify that the views expressed in this report accurately reflect my personal views about the subject companies and / or securities. I also certify that no part of my compensation are, is or will be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, I will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

### Other Disclosure

IDBI Capital Markets & Securities Ltd.(herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail) , Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on [www.idbic平臺.com](http://www.idbic平臺.com) IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Additionally, IDBI Capital generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital or its associates may have interest in the Companies under recommendation in this report either as Director or shareholder. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of IDBI Capital. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. We and our associates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. For the purpose of calculating whether IDBI Capital and its associates holds beneficially owns or controls, including the right to vote for directors, 1% of more of the equity shares of the subject issuer of a research report, the holdings does not include accounts managed by IDBI Asset Management Company/ IDBI Mutual Fund.

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates, during the normal course of business, from time to time, may solicit from or perform investment banking or other services for any company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the website of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital nor Research Analysts have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional investors and their employees, directors, fund managers, advisors who are registered with us. The Research Analyst has not served as an officer, director or employee of Subject Company. We or our associates may have received compensation from the subject company in the past 12 months. We or our associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. We or our associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. We or our associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research Analyst or his/her relatives may have financial interest in the subject company. IDBI Capital or its associates may have financial interest in the subject company. Research Analyst or his/her relatives does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. IDBI Capital or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. The Subject Company may have been a client during twelve months preceding the date of distribution of the research report. Price history of the daily closing price of the securities covered in this note is available at [www.bseindia.com](http://www.bseindia.com); [www.nseindia.com](http://www.nseindia.com) and [www.economictimes.indiatimes.com/markets/stocks/stock-quotes](http://www.economictimes.indiatimes.com/markets/stocks/stock-quotes).